COVID vaccination linked to hair loss
A report of nine cases of alopecia areata (AA) following SARS-CoV-2 vaccination appears to confirm suspicions that mRNA vaccines can trigger autoimmune responses that lead to hair loss…. read more.
A report of nine cases of alopecia areata (AA) following SARS-CoV-2 vaccination appears to confirm suspicions that mRNA vaccines can trigger autoimmune responses that lead to hair loss…. read more.
AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus… read more.
Patients treated for Merkel cell carcinoma (MCC) face a five-year recurrence rate of 40% — markedly higher than the recurrence rates for cand other skin cancers, according to… read more.
Acne on the face is often treated with topical antibiotics, which tend to be used for an extended period of time and contribute to the serious problem of… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced comprehensive efficacy and safety data from the DISCOVER–2 trial of Tremfya (guselkumab) were published in Arthritis & Rheumatology, representing… read more.
Research by the Oregon State University College of Pharmacy suggests that a vaccine stimulating production of a protein critical to the skin’s antioxidant network could help people bolster… read more.
Pfizer announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the 100 mg and 200 mg… read more.
New study shows there may be a way to help even more psoriasis patients. About 7.5 million Americans suffer from psoriasis, an autoimmune disease that shows up as… read more.
Horizon Therapeutics announced topline results of the phase III MIRROR trial met the primary endpoint, showing a significant increase in efficacy using Krystexxa (pegloticase injection) with the immunomodulator… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the FDA seeking expanded approval of Stelara (ustekinumab) to… read more.
ChemoCentryx announced that the FDA has approved Tavneos (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil… read more.
Incyte announced that the FDA has approved Opzelura (ruxolitinib) cream for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.